In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Biopharma’s wider visibility in the COVID-19 pandemic response and 2020’s public spotlight on diversity issues bring both challenges and opportunities for industry leaders going forward.

Building The Talent Pipeline Starts With Access For All

Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives. 

Rebuilding Reputations: COVID-19 Presents A Big Responsibility And Opportunity

The global COVID-19 crisis has presented a chance for industry to improve its reputation by highlighting the value of its R&D engines. Pharma executives and observers outline why they are optimistic about a chance to regain public trust.

Sanofi’s Berger On Creating A Sleek R&D Engine Fit For Purpose In The 2020s

A change in direction for the French firm means a new approach to R&D. Sanofi’s global head of development and chief medical officer Dietmar Berger talked to In Vivo about what was needed to get the company’s R&D machine back on track. 

Pharma CEO Pay Trends In India: What Lies Ahead?

In Vivo discusses dimensions around pharma CEO pay in India and whether it should be part of cost management efforts amid the pandemic.

Titans Of Pharma 2020: 15 Leading CEOs Bag $266m In Compensation

See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.

Chapter sponsored by:

COVID Brings CDMO Value, Strategic Partnerships Into Focus

The COVID-19 pandemic has brought into sharp focus the importance of an agile, reliable and efficient supply chain for pharmaceutical active ingredients and finished products.

Download Now

About Cambrex

Cambrex is the small molecule company that provides drug substance, drug product and analytical services across the entire drug lifecycle.

Learn More »